Next |
home / stock / etnb / etnb message board
Subject | By | Source | When |
---|---|---|---|
Very, very easy to unintentionally do in the | MiamiGent | investorshub | 06/23/2023 2:51:27 PM |
MG, I'm being told that I have you | back2basics | investorshub | 06/23/2023 2:52:57 AM |
MomentumIts trading last trade up | MiamiGent | investorshub | 06/19/2023 8:25:19 PM |
bulls and bears | BigBadWolf | investorshub | 06/19/2023 12:26:25 PM |
$ETNB Time for a bounce? | subslover | investorshub | 06/19/2023 3:54:18 AM |
Price now last up | subslover | investorshub | 06/17/2023 4:23:39 PM |
$ETNB Price gaining last up | subslover | investorshub | 06/17/2023 3:37:18 AM |
$ETNB bears and bulls | Invest-in-America | investorshub | 06/16/2023 11:43:42 AM |
$23.87 new 52 week high! | subslover | investorshub | 06/15/2023 7:15:48 PM |
MomentumIts gaining | subslover | investorshub | 06/15/2023 10:03:48 AM |
$ETNB The now | subslover | investorshub | 06/14/2023 3:28:00 AM |
$ETNB Thoughts on where this is headed? | subslover | investorshub | 06/14/2023 1:35:13 AM |
$ETNB short data if anyone is interested | subslover | investorshub | 06/13/2023 10:59:39 PM |
Good luck, subs. | MiamiGent | investorshub | 06/13/2023 8:07:02 PM |
Wow, the stock is $22.93 today a new | subslover | investorshub | 06/13/2023 6:32:03 PM |
$ETNB What do you make of this? | subslover | investorshub | 06/13/2023 10:41:13 AM |
Price trading last up | ollik78 | investorshub | 06/08/2023 7:04:34 AM |
The trading | Invest-in-America | investorshub | 06/06/2023 2:31:11 PM |
Thoughts on where this is headed? | subslover | investorshub | 06/06/2023 5:53:21 AM |
Price trading | subslover | investorshub | 06/05/2023 2:03:46 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...